Cogent Biosciences Inc
Abrir
33.42 -0.68
Visão Geral
Variação de preço das ações
24h
Mín
33.24
Máximo
34.83
Rendimento | 947K -96M |
|---|---|
EPS | -0.52 |
Funcionários | 258 |
EBITDA | 537K -94M |
Próximos Ganhos | 2 de nov. de 2026 |
|---|
Capitalização de Mercado | -608M 6B |
|---|---|
Abertura anterior | 34.1 |
Fecho anterior | 33.42 |
Cogent Biosciences Inc Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Notícias Relacionadas
Comparação entre Pares
Variação de preço
Cogent Biosciences Inc Previsão
Informação Financeira
Custos administrativos e de venda
Custos Operacionais
Lucro antes de imposto
Vendas
Custo das vendas
Lucro bruto sobre vendas
Despesa com juros da dívida
EBITDA
Resultado Operacional
$
Sobre Cogent Biosciences Inc
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.